Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Revakinagene taroretcel - Neurotech USA

Next Previous
Drug Profile

Revakinagene taroretcel - Neurotech USA

Alternative Names: Ciliary neurotrophic factor - Neurotech; Ciliary neurotrophic factor implant - Neurotech; CNTF implant - Neurotech; Encapsulated CNTF - Neurotech; ENCELTO; NT-501; Retinitis pigmentosa encapsulated cell therapy - Neurotech; Revakinagene taroretcel-lwey

Latest Information Update: 18 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurotech USA
  • Class Cell therapies; Eye disorder therapies; Gene therapies
  • Mechanism of Action Ciliary neurotrophic factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal telangiectasis; Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Marketed Retinal telangiectasis
  • Phase II/III Retinitis pigmentosa
  • Phase II Glaucoma; Usher syndromes
  • Phase I/II Colour vision defects
  • No development reported Dry macular degeneration; Ischaemic optic neuropathy

Most Recent Events

  • 11 Aug 2025 Launched for Retinal telangiectasis in USA (Intravitreous)
  • 06 Mar 2025 Neurotech plans to launch revakinagene taroretcel for Retinal telangiectasia in USA (Intraocular, Implant) in June 2025
  • 06 Mar 2025 Neurotech Pharmaceuticals initiates a phase III trial in Retinal telangiectasia in USA (Intravitreous, Implant) (NCT06397131)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top